US FDA declines to approve Scholar Rock’s muscle weakness drug; shares fall
NegativeFinancial Markets

The US FDA has declined to approve Scholar Rock's drug aimed at treating muscle weakness, leading to a significant drop in the company's shares. This decision is crucial as it not only impacts Scholar Rock's financial standing but also affects patients who are in need of effective treatments for muscle-related conditions. The setback highlights the challenges pharmaceutical companies face in bringing new drugs to market and raises questions about the future of similar therapies.
— Curated by the World Pulse Now AI Editorial System